Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 AlteredExpression group BEFREE In the univariate analysis, studies were separated by the study design, the number of metastatic sites, the site of metastases, radiotherapy machine, and prostate-specific antigen level at the time of SBRT. 31809327 2020
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 Biomarker group BEFREE In the multivariate analysis, the Gleason score, PSA and presence of metastases were associated with shorter OS and PFS. 29891440 2020
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 AlteredExpression group BEFREE The study confirmed that patients with high PSA level and fast PSA increase are likely to be diagnosed with both, local relapse and metastases. 31568268 2019
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 Biomarker group BEFREE The correlation between PSA value and presence of metastases confirms the usefulness of bone scan scintigraphy in prostate cancer staging. 30900618 2019
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 Biomarker group BEFREE It found that PSA-based screening in men aged 55 to 69 years prevents approximately 1.3 deaths from prostate cancer over 13 years per 1000 men screened and 3 cases of metastatic cancer per 1000 men screened, with no reduction in all-cause mortality. 31158876 2019
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 Biomarker group BEFREE A significant (p ≤ 0.05) correlation between SUV<sub>max</sub> in PSMA-positive liver metastases and both size (ρ<sub>Spearman</sub> = 0.57) of metastases and PSA serum level (ρ<sub>Spearman</sub> = 0.60) was found. 31186052 2019
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 Biomarker group BEFREE PSA ≥ 5.5 ng/mL, locoregional nodal involvement determined by pathology (pN1), prior primary radiation, and prior salvage radiotherapy independently predicted M1 disease (all <i>P</i> < 0.05). 31511295 2019
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 AlteredExpression group BEFREE Median PSA level was 142ng/ml and 67% of patients had more than five osseous metastases.Median follow up was 47 mo. 30266309 2019
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 AlteredExpression group BEFREE In univariate analyses, post-neoAS, pre-RT PSA level >0.1 ng/mL was associated with increased risks of biochemical failure (hazard ratio [HR], 2.04; P < .0001); local failure (HR, 2.51; P < .0001); distant metastases (HR, 1.73; P = .0006); cause-specific mortality (HR, 2.36; P < .0001); and all-cause mortality (HR, 1.24; P = .005). 30959123 2019
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 AlteredExpression group BEFREE These patients were subdivided by PSA level (0-9.9, 10.0-19.9, 20.0-39.9, 40.0-59.9, 60.0-79.9, 80.0-97.9, and ≥98.0 ng/mL), nodal status (N0 vs N1), and distant metastases (M0 vs M1). 31390585 2019
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 Biomarker group BEFREE The other five cases (median PSA, 7.41 ng/mL) had multiple metastases and systemic therapies were continued in those cases. 31325132 2019
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 Biomarker group BEFREE Although our observational study design cannot pinpoint the exact cause of this increase, which is likely multifactorial, this shift reverses declines in metastases at diagnoses that followed the advent of prostate-specific antigen screening. 31522862 2019
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 AlteredExpression group BEFREE Although the percentage of patients with GS ≥ 8 or metastases increased as PSA levels increased up to approximately 70 ng / mL, there was no significant increase between 70 and 100 ng / mL. 30521173 2019
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 AlteredExpression group BEFREE Although it is generally accepted that higher PSA values indicate higher disease burden, few data are available on the relation between PSA levels and number of detected metastases on PSMA PET/CT. 31274553 2019
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 Biomarker group BEFREE The Cox proportional hazards regression model was used to assess the prognostic importance of race (black v white) adjusted for established risk factors common across the trials (age, prostate-specific antigen, performance status, alkaline phosphatase, hemoglobin, and sites of metastases). 30576268 2019
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 Biomarker group BEFREE Data of age, clinical stage, Gleason grade(GG), previous treatments, site of metastases, Prostate-specific antigen (PSA) values, TTCR, overall survival, biochemical progression free survival(PFS) and PSA response to docetaxel were recorded. 30636274 2019
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 Biomarker group BEFREE Significant differences in AUCs for IL-35 and prostate-specific antigen were observed with regard to the presence of lymph node and distant metastases in patients with PCA. 31186721 2019
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 AlteredExpression group BEFREE Data on previous treatments, serum PSA levels (ng/mL), 68 Ga-PSMA-I&T PET/CT findings metastases as well as survival data were recorded. 30006752 2018
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 AlteredExpression group BEFREE [68Ga]PSMA-11, which is the most frequently applied tracer, has shown to detect lymph node metastases, local recurrences, distant metastases and intraprostatic foci with high sensitivity, even at relatively low PSA levels. 29869483 2018
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 AlteredExpression group BEFREE CONCLUSIONS The urinary sarcosine/creatinine ratio was a diagnostic indicator of prostate cancer, for patients with a serum PSA level <10 ng/ml, and correlated with the Gleason score and with the presence of metastases (stage) of prostate cancer. 29741162 2018
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 AlteredExpression group BEFREE Particularly in patients with PSA levels above 1.0 ng/mL, a <sup>68</sup>Ga-PSMA ligand PET/CT should be performed for therapy planning, since patients often have metastases not confined to the pelvis. 29134231 2018
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 Biomarker group BEFREE Univariable Cox regression determined pathological Gleason grade (P = 0.021), seminal vesicle invasion (P = 0.010), and first postoperative PSA ≥0.2 ng/ml (P = 0.005) were associated with metastases. 29429895 2018
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 Biomarker group BEFREE In stage D0, the Prostate-Specific Antigen (PSA) slope is prognostic of time to radiographic evidence of metastases and death. 29143114 2018
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 Biomarker group BEFREE Those with an early prostate specific antigen doubling time of 3 to 8.9 months were at increased risk for castration resistant prostate cancer (HR 3.56, p = 0.015), all cause mortality (HR 1.67, p = 0.006) and prostate cancer specific mortality (HR 3.17, p = 0.044) but not metastases (p = 0.13). 28870860 2018
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 GeneticVariation group BEFREE The number of sites (prostate bed, lymph nodes, distant metastases) with positive PSMA uptake was significantly associated with PSA values before imaging (P = 0.0032). 29777523 2018